Loading articles...
Patients with chronic dermatologic conditions face a delicate balance between disease control and infection risk when using JAK inhibitors and biologics. This meta-analysis prompts clinicians to carefully evaluate individual patient risk profiles before ini...
Acne recurrence remains a frustrating challenge for both patients and dermatologists, impacting quality of life. This study attempts to identify key risk factors and develop a predictive model to mitigate this issue.
Dermatology patients on advanced immunomodulatory therapies face an elevated risk of infection, demanding vigilant monitoring. This meta-analysis prompts a crucial reevaluation of comparative safety profiles between JAK inhibitors and biologics in managing ...
Patients with atopic dermatitis (AD) are benefiting from the shift toward targeted systemic therapies that avoid broad immunosuppression. The evolution towards biologics and JAK inhibitors promises more precise management and fewer off-target effects, thoug...
The discovery of two new Mycobacterium species, *Mycobacterium camsae* and *Mycobacterium pumcae*, isolated from human skin infections, highlights the ongoing evolution of our understanding of microbial diversity. Clinicians should consider that conventiona...
A recent case highlights the efficacy of spesolimab in treating an acute flare of generalized pustular psoriasis (GPP) with severe erythema and plaques. This success reinforces the IL-36 pathway as a critical therapeutic target in autoinflammatory skin dise...
Rising Staphylococcus aureus resistance in atopic dermatitis threatens the effectiveness of common topical treatments. This demands a reevaluation of antimicrobial stewardship programs to preserve treatment options and reduce healthcare costs.
Rising antibiotic resistance in Staphylococcus aureus complicates atopic dermatitis treatment. This UK study prompts a re-evaluation of first-line topical therapies to preserve their effectiveness.
Atopic dermatitis treatment is being complicated by the changing face of antimicrobial resistance. Clinicians need to anticipate further shifts in resistance patterns to maintain effective treatment strategies, especially regarding topical agents.